Compared to controls, both CK-B levels and activity were decreased in subjects with MS (22.41 versus 46.28 μg/ml; p = 0.0007, and 2.89 versus 7.76 U/l; p<0.0001). This evidence concerns the gene CKB and myeloid sarcoma.